Market closedNon-fractional
Profound Medical/PROF
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Profound Medical
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Ticker
PROF
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Mississauga, Canada
Employees
131
Website
www.profoundmedical.com
Profound Medical Metrics
BasicAdvanced
$266M
Market cap
-
P/E ratio
-$1.27
EPS
0.81
Beta
-
Dividend rate
Price and volume
Market cap
$266M
Beta
0.81
Financial strength
Current ratio
5.41
Quick ratio
4.645
Long term debt to equity
1.093
Total debt to equity
15.779
Interest coverage (TTM)
-38.75%
Management effectiveness
Return on assets (TTM)
-30.83%
Return on equity (TTM)
-59.26%
Valuation
Price to revenue (TTM)
33.089
Price to book
8.15
Price to tangible book (TTM)
8.23
Price to free cash flow (TTM)
-11.119
Growth
Revenue change (TTM)
1.00%
Earnings per share change (TTM)
-2.37%
3-year revenue growth (CAGR)
1.88%
3-year earnings per share growth (CAGR)
-3.45%
What the Analysts think about Profound Medical
Analyst Ratings
Majority rating from 2 analysts.
Profound Medical Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.9M
-5.00%
Net income
-$6.1M
-31.46%
Profit margin
-321.05%
-27.85%
Profound Medical Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.35
-$0.26
-$0.42
-$0.26
-
Expected
-$0.35
-$0.34
-$0.32
-$0.28
-$0.29
Surprise
-1.36%
-22.71%
31.46%
-5.45%
-
Profound Medical News
AllArticlesVideos
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
GlobeNewsWire·1 week ago
Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases
GlobeNewsWire·2 weeks ago
Profound Medical Annual General Meeting of Shareholders Voting Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Profound Medical stock?
Profound Medical (PROF) has a market cap of $266M as of July 27, 2024.
What is the P/E ratio for Profound Medical stock?
The price to earnings (P/E) ratio for Profound Medical (PROF) stock is 0 as of July 27, 2024.
Does Profound Medical stock pay dividends?
No, Profound Medical (PROF) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Profound Medical dividend payment date?
Profound Medical (PROF) stock does not pay dividends to its shareholders.
What is the beta indicator for Profound Medical?
Profound Medical (PROF) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Profound Medical stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.